snf2相关蛋白在癌症中的作用。

Ernst Schering Research Foundation workshop Pub Date : 2006-01-01 DOI:10.1007/3-540-37633-x_3

T Owen-Hughes

{"title":"snf2相关蛋白在癌症中的作用。","authors":"T Owen-Hughes","doi":"10.1007/3-540-37633-x_3","DOIUrl":null,"url":null,"abstract":"Several HDAC inhibitors that exhibit impressive anti-tumour activity are now in clinical trials. Proteins that function in the same pathways might also serve as valuable therapeutic targets. A subset of histone deacetylase activities are found to be physically associated with ATP-dependent remodelling enzymes and may assist their function. This raises the possibility that ATP-dependent remodelling enzymes should be considered as therapeutic targets. Here some of the links between ATP-dependent chromatin remodelling enzymes and cancer are reviewed.","PeriodicalId":80277,"journal":{"name":"Ernst Schering Research Foundation workshop","volume":" 57","pages":"47-59"},"PeriodicalIF":0.0000,"publicationDate":"2006-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/3-540-37633-x_3","citationCount":"2","resultStr":"{\"title\":\"The role of Snf2-related proteins in cancer.\",\"authors\":\"T Owen-Hughes\",\"doi\":\"10.1007/3-540-37633-x_3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Several HDAC inhibitors that exhibit impressive anti-tumour activity are now in clinical trials. Proteins that function in the same pathways might also serve as valuable therapeutic targets. A subset of histone deacetylase activities are found to be physically associated with ATP-dependent remodelling enzymes and may assist their function. This raises the possibility that ATP-dependent remodelling enzymes should be considered as therapeutic targets. Here some of the links between ATP-dependent chromatin remodelling enzymes and cancer are reviewed.\",\"PeriodicalId\":80277,\"journal\":{\"name\":\"Ernst Schering Research Foundation workshop\",\"volume\":\" 57\",\"pages\":\"47-59\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/3-540-37633-x_3\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ernst Schering Research Foundation workshop\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/3-540-37633-x_3\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ernst Schering Research Foundation workshop","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/3-540-37633-x_3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

摘要

几种表现出令人印象深刻的抗肿瘤活性的HDAC抑制剂目前正在临床试验中。在相同途径中起作用的蛋白质也可能作为有价值的治疗靶点。组蛋白去乙酰化酶活性的一个子集被发现与atp依赖性重构酶物理相关，并可能有助于其功能。这提出了atp依赖性重塑酶应被视为治疗靶点的可能性。本文综述了atp依赖性染色质重塑酶与癌症之间的一些联系。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

The role of Snf2-related proteins in cancer.

Several HDAC inhibitors that exhibit impressive anti-tumour activity are now in clinical trials. Proteins that function in the same pathways might also serve as valuable therapeutic targets. A subset of histone deacetylase activities are found to be physically associated with ATP-dependent remodelling enzymes and may assist their function. This raises the possibility that ATP-dependent remodelling enzymes should be considered as therapeutic targets. Here some of the links between ATP-dependent chromatin remodelling enzymes and cancer are reviewed.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ernst Schering Research Foundation workshop

自引率

0.00%

发文量

期刊最新文献

Experiences with dose finding in patients in early drug development: the use of biomarkers in early decision making. Genotype and phenotype relationship in drug metabolism. Clinical trials in elderly patients. Dose finding in pediatric patients. Integration of pediatric aspects into the general drug development process.